Abstract
Coronavirus disease 2019 (COVID-19), during the second wave in early 2021, has created disastrous chaos. Adding more burdens to such a challenging situation, mucormycosis is an angioinvasive, fulminant fungal infection has seen a sudden raise in patients with COVID-19. Mucormycosis commonly affects the patients with compromised immunity. Early diagnosis, elimination of the predisposing factor, and antifungal therapy along with surgical debridement are the key factors responsible for successful treatment and patient survival. Mucormycosis is presented by various clinical forms. This paper reviews about the clinical presentation, diagnosis, and various treatment modalities for managing mucormycosis patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
